Therapeutic agent for motor disorders
Provided are an agent for the treatment and/or prophylaxis of a movement disorder, the agent for the treatment and/or prophylaxis wherein the movement disorder is extrapyramidal syndrome, the agent for the treatment and/or prophylaxis wherein the movement disorder is bradykinesia, gait disturbance, dystonia, dyskinesia or tardive dyskinesia, the agent for the treatment and/or prophylaxis wherein the movement disorder is a side effect of L-DOPA and/or dopamine agonist therapy, and the like, each containing a thiazole derivative represented by the formula (I) wherein R 1 represents aryl and the like, and R 2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof as an active ingredient.
1. A compound represented by any one of the following formulae (IE)-(IAA), or a pharmaceutically acceptable salt thereof:
2. A pharmaceutical composition, comprising:
(a) a thiazole derivative represented by formula (IC)
or a pharmaceutically acceptable salt thereof, and
(b) L-DOPA and/or a dopamine agonist.
3. A kit, comprising:
(a) a first component comprising a thiazole derivative represented by formula (IC)
or a pharmaceutically acceptable salt thereof, and
(b) a second component comprising L-DOPA and/or a dopamine agonist.
4. A combination, comprising:
(a) a thiazole derivative represented by formula (IC)
or a pharmaceutically acceptable salt thereof, and
(b) L-DOPA and/or a dopamine agonist, for use in the treatment and/or prophylaxis of Parkinson's disease.
5. The combination according to claim 4 , wherein (a) and (b) are administered simultaneously.
6. The combination according to claim 4 , wherein (a) and (b) are administered separately at an interval.
7. A method of treating and/or preventing progression of Parkinson's disease, comprising the steps of:
administering to a patient simultaneously or separately at an interval
(a) an effective amount of a thiazole derivative represented by formula (IC)
or a pharmaceutically acceptable salt thereof, and
(b) an effective amount of L-DOPA and/or a dopamine agonist.
8. The method according to claim 7 , wherein (a) and (b) are administered simultaneously.
9. The method according to claim 7 , wherein (a) and (b) are administered separately at an interval.
10. A method of treating and/or preventing progression of Parkinson's disease, comprising the steps of:
selecting a compound represented by any of formulae (IE)-(IAA) or a pharmaceutically acceptable salt thereof according to claim 1 ; and
administering to a patient simultaneously or separately at an interval
(a) an effective amount of said compound or pharmaceutically acceptable salt, and
(b) an effective amount of L-DOPA and/or a dopamine agonist.
11. The method according to claim 10 , wherein (a) and (b) are administered simultaneously.
12. The method according to claim 10 , wherein (a) and (b) are administered separately at an interval.